1 – 10 of 163
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2026
-
Mark
Censoring imbalances in randomized first-line trials of chronic lymphocytic leukemia
(2026) In Leukemia and Lymphoma
- Contribution to journal › Letter
-
Mark
Chromatin landscape and epigenetic heterogeneity of acute myeloid leukaemia
(2026) In Nature
- Contribution to journal › Article
-
Mark
Updated consensus guidelines for the diagnosis and management of patients with HCL and HCL variant
(2026) In Blood
- Contribution to journal › Debate/Note/Editorial
-
Mark
Intensive Chemotherapy and Tyrosine Kinase Inhibitor in Patients with De Novo BCR::ABL1+ Acute Myeloid Leukemia
(2026) In Blood
- Contribution to journal › Article
- 2025
-
Mark
Risk of infections in multiple myeloma. A population-based study on 8,672 multiple myeloma patients diagnosed 2008-2021 from the Swedish Myeloma Registry
- Contribution to journal › Article
-
Mark
Income and education affect prognosis and treatment in symptomatic myeloma : A population-based study on 8672 multiple myeloma patients diagnosed 2008–2021 from the Swedish myeloma registry
- Contribution to journal › Article
-
Mark
Aberrant expression of SLAMF6 constitutes a targetable immune escape mechanism in acute myeloid leukemia
- Contribution to journal › Article
-
Mark
The AML cellular state space unveils NPM1 immune evasion subtypes with distinct clinical outcomes
- Contribution to journal › Article
-
Mark
Second- and Third-Line Salvage Chemotherapy Followed by Allogeneic Stem Cell Transplantation Leads to High Survival Rates in Primary Refractory AML—A Population-Based Study
- Contribution to journal › Article
-
Mark
The impact of fitness and dose intensity on clinical outcomes with venetoclax-obinutuzumab in CLL
- Contribution to journal › Article
